# Evaluating the Safety, Tolerability, and Immunogenicity of a Tetravalent Dengue Vaccine (V180) in Healthy Adults Who Previously Received a Live-Attenuated Tetravalent Vaccine (TV003 or TV005)

> **NCT02450838** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 20 (actual)

## Conditions studied

- Dengue

## Interventions

- **BIOLOGICAL:** V180
- **BIOLOGICAL:** Alhydrogel™
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT02450838
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04
- **Primary completion:** 2015-10
- **Final completion:** 2015-10
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2016-04-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02450838

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02450838, "Evaluating the Safety, Tolerability, and Immunogenicity of a Tetravalent Dengue Vaccine (V180) in Healthy Adults Who Previously Received a Live-Attenuated Tetravalent Vaccine (TV003 or TV005)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02450838. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*